Key Takeaways C3.ai, Inc. (AI) is doubling down on a go-to-market strategy centered around its rapidly expanding partner ecosystem. In the fourth quarter of fiscal 2025, the company secured 73% of its agreements in collaboration with strategic partners like Microsoft, AWS and Google Cloud. In fiscal 2025, it signed 193 deals through the partner ecosystem, reflecting a rise of 68% from the prior year. In the fiscal fourth quarter, AI reported a 419% surge in partner-supported bookings, with 59 agreements clo ...

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today June 23rd: Strattec Security has a PEG ratio of 1.30 compared with 4.04 for the industry. The company possesses a Growth Score of A. European Wax Center (EWCZ) : This personal care franchise brand which offers wax services from certified Wax Specialists as well as full collection of proprietary products in the skincare, body and brow categories, carries a Zacks Rank #1, and has witnessed the Zacks Consensu ...

Key Takeaways UGI Corporation (UGI) announced that its subsidiary, AmeriGas Propane, L.P. (AmeriGas), has entered into a definitive agreement to divest some of its assets in Hawaii to Isle Gas, a wholly owned subsidiary of AMF Hawaii Investment Holdings, LLC, managed by Argo Infrastructure Partners. The transaction is expected to be closed in the fourth quarter of fiscal 2025, subject to customary closing conditions. What Are UGI's Gains From This Sale? Sempra Energy (SRE) is divesting certain assets as par ...

Key Takeaways J&J (JNJ) announced that the EMA's Committee for Medicinal Products for Human Use ("CHMP") recommended granting label expansion to its two key products, Darzalex and Imbruvica, across separate new indications. CHMP Endorses JNJ's Darzalex for a New Multiple Myeloma Setting The EMA committee has issued a positive opinion for expanding Darzalex's label to treat adults with smoldering multiple myeloma (SMM), who are at high risk of developing multiple myeloma. If approved, the drug will be the fi ...

公司国际业务表现 - 埃森哲2025年5月季度总营收达177.3亿美元 同比增长7.7% [4] - 欧洲、中东和非洲地区营收62.3亿美元 占总额35.15% 超出华尔街预期1.75% [5] - 亚太地区营收25.3亿美元 占比14.27% 较预期高出13.97% [6] 区域营收历史对比 - 欧洲、中东和非洲地区上季度营收58亿美元(34.84%) 去年同期57.8亿美元(35.08%) [5] - 亚太地区上季度营收23亿美元(13.82%) 去年同期28.6亿美元(17.34%) [6] 市场预期与预测 - 华尔街预计当前财季总营收169.9亿美元 同比增长3.6% [7] - 预计欧洲、中东和非洲地区营收占比35.3%(60亿美元) 亚太地区14%(23.7亿美元) [7] - 全年营收预期688.6亿美元 同比增长6.1% 欧洲、中东和非洲预计占比35.4%(243.7亿美元) 亚太14.6%(100.7亿美元) [8] 股票市场表现 - 过去一个月股价下跌7.8% 同期标普500指数上涨0.5% [13] - 三个月累计跌幅6.2% 同期行业板块上涨10% 标普500上涨5.6% [13] - 所属计算机与科技板块近月上涨2.5% [13] 分析师评级 - 当前Zacks评级为3级(持有) 预示短期表现可能与大盘同步 [12] - 盈利预测上调通常伴随股价上涨 该评级系统已验证对短期走势的预测能力 [11]

季度业绩预测 - 华尔街分析师预测公司季度每股收益(EPS)为1.36美元，同比下降3.6% [1] - 预计季度营收为1.6201亿美元，同比增长16.4% [1] - 过去30天内分析师对EPS的共识预测保持稳定，显示整体预期未调整 [1] 业绩预测与股价关联性 - 财报公布前的盈利预测修订对预测投资者反应具有关键作用 [2] - 实证研究表明盈利预测趋势与股票短期价格波动存在强相关性 [2] 关键业务指标预测 - 基础设施板块营业收入预计2575万美元，同比增长5.7% [4] - 灌溉板块营业收入预计1.3626亿美元，同比增长18.7% [4] - 灌溉板块营业利润预计2141万美元，较上年同期的1952万美元增长 [5] - 基础设施板块营业利润预计474万美元，低于上年同期的628万美元 [5] 股价表现与市场对比 - 公司股价过去一个月下跌1.6%，同期标普500指数上涨0.5% [6] - 当前Zacks评级为3级(持有)，预计未来表现将与整体市场一致 [6]

公司业绩预期 - 预计季度每股收益为0 11美元 同比下滑89 1% [1] - 预计营收为10 67亿美元 同比下降15 4% [1] - 过去30天内分析师将每股收益预期下调2 3% [1] 收入分项预测 - Converse品牌收入预计4 2827亿美元 同比下滑10 8% [4] - 全球品牌部门收入预计1151万美元 同比增长4 6% [4] - 服装类收入预计29 4亿美元 同比下降11 5% [4] - 装备类收入预计5 5019亿美元 同比下降4 8% [5] 区域收入预测 - 北美地区收入预计44 8亿美元 同比下降15 2% [5] - 亚太及拉美地区收入预计15亿美元 同比下降12 1% [5] - 欧洲中东非洲地区收入预计28 3亿美元 同比下降14% [6] - 大中华区收入预计14 8亿美元 同比下降20 4% [6] - 耐克品牌全球总收入预计103 3亿美元 同比下降15% [6] 区域品类细分 - 亚太及拉美地区服装收入预计3 7736亿美元 同比下降9 3% [7] - 亚太及拉美地区鞋类收入预计10 6亿美元 同比下降13 2% [7] - 欧洲中东非洲地区装备收入预计1 5752亿美元 同比下降10 5% [8] 市场表现 - 过去一个月公司股价下跌0 4% 同期标普500指数上涨0 5% [8] - 当前Zacks评级为3级(持有) 预计表现将与市场整体持平 [8][9]

In its upcoming report, Acuity (AYI) is predicted by Wall Street analysts to post quarterly earnings of $4.31 per share, reflecting an increase of 3.9% compared to the same period last year. Revenues are forecasted to be $1.14 billion, representing a year-over-year increase of 17.5%. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this ...

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. That said, let's delve into the average estimates of some McCormick metrics that Wall Street analysts commonly model and monitor. It is projected by analysts that the 'Net Sales- Flavor Solutions' will reach $746.82 million. The estimate points to a change of +1.1% from the ye ...

核心观点 - 公司即将发布的季度每股收益预计为0.34美元，同比下降46% [1] - 分析师预计公司季度营收为366.6亿美元，同比增长0.9% [1] - 过去30天分析师对每股收益的共识预期保持不变 [1] 财务表现 - 美国零售药房业务收入预计为287.6亿美元，同比增长0.9% [4] - 美国医疗保健业务收入预计为21.7亿美元，同比增长2.3% [4] - 国际业务收入预计为57.4亿美元，同比增长0.2% [4] 运营利润 - 美国零售药房业务调整后运营利润预计为1.1367亿美元，去年同期为5.01亿美元 [5] - 国际业务调整后运营利润预计为1.9639亿美元，去年同期为1.75亿美元 [5] 股价表现 - 公司股价在过去一个月上涨1.3%，同期标普500指数上涨0.5% [5] - 公司目前Zacks评级为2级（买入），预计短期内将跑赢大盘 [5]